The Cell Engineering Shared Resource (CESR; formerly called the Cell and Viral Vector laboratory), established in 1976, was the first Shared Resource established by the Atrium Health Wake Forest Baptist Comprehensive Cancer Center (AHWFBCCC).
The mission of the CESR is to serve the scientific needs of AHWFBCCC researchers at Winston-Salem and Charlotte campuses by offering specialized cell culture services with an emphasis on genetic engineering of cancer cell lines for individual projects with stringent quality control.
The CESR offers user-customizable production of a variety of vectors to enable AHWFBCCC members to maximize research productivity. The CESR houses advanced instrumentation for monitoring cell proliferation in vivo and in vitro. Additionally, it is a central facility for purchasing and distributing specific culture media and reagents, molecular biology kits, and standard laboratory supplies, while providing effective distribution to researchers at additional no cost.
Focus Areas
- Generation and characterization of genetically engineered cell models for cancer and translational research.
- Maintenance of authenticated cell resources and promotion of reproducible cell culture practices.
- Support of in vitro and in vivo studies through advanced imaging and analytical platforms.
- Stockroom: A centralized procurement and distribution of cell culture media, same-lot FBS, reagents, and laboratory consumables.
- Education, consultation, and technical training in cell engineering, cell culture, and imaging technologies.
Services and Capabilities
|
Cell Engineering and Development
|
|
IVIS Imaging and Quality Control
|
|
Stockroom and Supply Chain Support
|
- Das U, Behl A, Gmeiner WH. The fluoropyrimidine polymer CF10 synergizes with 5-ethynyl-2'-deoxyuridine by promoting telomere attrition and mitotic catastrophe. NAR Mol Med. 2026 Jan 23;3(1):ugag005.
- Behl A, Young TM, Ma X, Cedrone E, Dobrovolskaia MA, Whitesides JF, Gmeiner WH. Activation of an adaptive antitumor immune response by the polymeric fluoropyrimidine CF10 involves TS/Top1 dual targeting. Biomed Pharmacother. 2026 Jun;199:119399.
- Young TM, Moumouni R, Behl A, Das U, Gmeiner WH. CF10 Displays Improved Synergy with Oxaliplatin in TP53-Null and Wild-Type CRC Cells from Increased Top1cc and Replication Stress. Cancers (Basel). 2026 Mar 9;18(5):882.
- Sarkar S, Behl A, Gmeiner WH. LNP-Mediated CF10 Delivery Selectively Enhances Potency to Colorectal Cancer Cells and Preserves the TS/Top1 Dual Targeting Mechanism. ACS Appl Bio Mater. 2026 Feb 16;9(4):1989-1997.
- Okechukwu CC, Gmeiner WH. CF10/LV overcomes acquired resistance to 5-FU/LV in colorectal cancer cells through downregulation of the c-Myc/ABCB5 axis. Cancer Drug Resist. 2025 Jul 15;8:35.
- Okechukwu CC, Ma X, Li W, D'Agostino R Jr, Rees MG, Ronan MM, Roth JA, Gmeiner WH. CF10 Displayed Improved Activity Relative to 5-FU in a Mouse CRLM Model Under Conditions of Physiological Folate. Cancers (Basel). 2025 Aug 23;17(17):2739.
- Zhao D, Deshpande R, Wu K, Tyagi A, Sharma S, Wu SY, Xing F, O'Neill S, Ruiz J, Lyu F, Watabe K. Identification of TUBB3 as an immunotherapy target in lung cancer by genome wide in vivo CRISPR screening. Neoplasia. 2025 Feb;60:101100.
- Finan JM, Di Niro R, Park SY, Jeong KJ, Hedberg MD, Smith A, McCarthy GA, Haber AO, Muschler J, Sears RC, Mills GB, Gmeiner WH, Brody JR. The polymeric fluoropyrimidine CF10 overcomes limitations of 5-FU in pancreatic ductal adenocarcinoma cells through increased replication stress. Cancer Biol Ther. 2024 Dec 31;25(1):2421584.
- Snyder CM, Mateo B, Patel K, Fahrenholtz CD, Rohde MM, Carpenter R, Singh RN. Enhancement of Triple-Negative Breast Cancer-Specific Induction of Cell Death by Silver Nanoparticles by Combined Treatment with Proteotoxic Stress Response Inhibitors. Nanomaterials (Basel). 2024 Sep 27;14(19):1564.
- Wang Y, Smith M, Ruiz J, Liu Y, Kucera GL, Topaloglu U, et al. Modulation of oxidative phosphorylation and mitochondrial biogenesis by cigarette smoke influence the response to immune therapy in NSCLC patients. Lung Cancer 2023;178:37-46.
- Smith MR, Wang Y, D'Agostino R, Jr., Liu Y, Ruiz J, Lycan T, et al. Prognostic Mutational Signatures of NSCLC Patients treated with chemotherapy, immunotherapy and chemoimmunotherapy. NPJ Precis Oncol 2023;7:34.
- Langsten KL, Shi L, Wilson AS, Lumia S, Westwood B, Skeen AM, Xie MT, Surratt VE, Turner J, Langefeld CD, Singh R, Cook KL, Kerr BA.Cancers (Basel). 2023 Dec 9;15(24):5773.
- Maracaja L, Khanna AK, Murphy SV, Maracaja DLV, Lane MR, Khoury O, et al. Positron Emission Tomography-Computed Tomography Imaging of Selective Lobar Delivery of Stem Cells in Ex Vivo Lung Model of Mechanical Ventilation. J Aerosol Med Pulm Drug Deliv 2023;36:20-6.
- Zhao D, Wu K, Sharma S, Xing F, Wu SY, Tyagi A, et al. Exosomal miR-1304-3p promotes breast cancer progression in African Americans by activating cancer-associated adipocytes. Nat Commun 2022;13:7734.
- Tyagi A, Wu SY, Sharma S, Wu K, Zhao D, Deshpande R, et al. Exosomal miR-4466 from nicotine-activated neutrophils promotes tumor cell stemness and metabolism in lung cancer metastasis. Oncogene 2022;41:3079-92.
- Tian C, Wei Y, Li J, Huang Z, Wang Q, Lin Y, et al. A Novel CDK4/6 and PARP Dual Inhibitor ZC-22 Effectively Suppresses Tumor Growth and Improves the Response to Cisplatin Treatment in Breast and Ovarian Cancer. Int J Mol Sci 2022;23.
- Sirkisoon SR, Wong GL, Aguayo NR, Doheny DL, Zhu D, Regua AT, et al. Breast cancer extracellular vesicles-derived miR-1290 activates astrocytes in the brain metastatic microenvironment via the FOXA2-->CNTF axis to promote progression of brain metastases. Cancer Lett 2022;540:215726.
- Locatelli M, Lawrimore J, Lin H, Sanaullah S, Seitz C, Segall D, et al. DNA damage reduces heterogeneity and coherence of chromatin motions. Proc Natl Acad Sci U S A 2022;119:e2205166119.
- Liu Y, Wang L, Song Q, Ali M, Crowe WN, Kucera GL, et al. Intrapleural nano-immunotherapy promotes innate and adaptive immune responses to enhance anti-PD-L1 therapy for malignant pleural effusion. Nat Nanotechnol 2022;17:206-16.
- Ghoneum A, Gonzalez D, Afify H, Shu J, Hegarty A, Adisa J, et al. Compound C Inhibits Ovarian Cancer Progression via PI3K-AKT-mTOR-NFkappaB Pathway. Cancers (Basel) 2022;14.
- Foster BM, Shi L, Harris KS, Patel C, Surratt VE, Langsten KL, et al. Bone Marrow-Derived Stem Cell Factor Regulates Prostate Cancer-Induced Shifts in Pre-Metastatic Niche Composition. Front Oncol 2022;12:855188.
- Deshpande RP, Sharma S, Liu Y, Pandey PR, Pei X, Wu K, et al. LncRNA IPW inhibits growth of ductal carcinoma in situ by downregulating ID2 through miR-29c. Breast Cancer Res 2022;24:6.